JUNO Profile
Juno Therapeutics, Inc. (JUNO) is a biotechnology company based in Seattle, Washington that focuses on developing innovative cellular immunotherapies for cancer. The company is known for its chimeric antigen receptor (CAR) T cell therapy, which involves taking a patient's own T cells and genetically modifying them to target and destroy cancer cells.
Juno Therapeutics has a number of ongoing clinical trials investigating the efficacy of its CAR T cell therapy in treating various types of cancer, including leukemia, lymphoma, and multiple myeloma. The company has also developed a number of partnerships with other pharmaceutical companies to advance its research and development efforts.
Juno Therapeutics was founded in 2013 and went public in 2014. In early 2018, the company was acquired by Celgene Corporation, a subsidiary of Bristol-Myers Squibb, in a deal valued at approximately $9 billion. The acquisition allowed Bristol-Myers Squibb to expand its pipeline of oncology treatments and position itself as a leader in the field of cellular immunotherapy.
As of its acquisition by Celgene Corporation, Juno Therapeutics had a market capitalization of approximately $9 billion.
|
